DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS Cediranib plus olaparib improved rPFS in men with mCRPC compared to olaparib alone. This combination was linked to an increase in the occurrence of grade 3-4 adverse events. BRCA2-mutated subgroups receiving olaparib with or without cediranib had a numerically longer median rPFS.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
